What is the role of rituximab in idiopathic membranous nephropathy?

Expert Review of Clinical Immunology

Volumn 9, Issue 1, 2013, Pages 13-16

  Ponticelli, Claudio ^a  

^a Istituto Scientifico Humanitas   (Italy)

Author keywords

adrenocorticotropic hormone; alkylating agents; calcineurin inhibitors; membranous nephropathy; mycophenolate; nephrotic syndrome; proteinuria; rituximab

Indexed keywords

ALBUMIN; ALKYLATING AGENT; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CORTICOSTEROID; CORTICOTROPIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS;

ALBUMIN BLOOD LEVEL; ARTICLE; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GONADAL DISEASE; HUMAN; IDIOPATHIC MEMBRANOUS NEPHROPATHY; INFUSION RELATED REACTION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MONOTHERAPY; NEOPLASM; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84871571068     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.89     Document Type: Article

References (22)

1. Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361(1), 11-21 (2009).
2. Murtas C, Bruschi M, Candiano G et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin. J. Am. Soc. Nephrol. 7(9), 1394-1400 (2012).
3. Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am. J. Kidney Dis. 25(6), 862-875 (1995).
4. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E. Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int. 51(3), 901-907 (1997).
5. Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N. Engl. J. Med. 329(2), 85-89 (1993).
6. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 48(5), 1600-1604 (1995).
7. Jha V, Ganguli A, Saha TK et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 18(6), 1899-1904 (2007).
8. Mathieson PW, Turner AN, Maidment CG, Evans DJ, Rees AJ. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 2(8616), 869-872 (1988).
9. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy. Am. J. Kidney Dis. 46(6), 1012-1029 (2005).
10. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. Am. J. Kidney Dis. 44(3), 385-401 (2004).
11. Cattran DC, Appel GB, Hebert LA et al.; North America Nephrotic Syndrome Study Group. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int. 59(4), 1484-1490 (2001).
12. Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int. 71(9), 924-930
13. Ponticelli C, Passerini P, Salvadori M et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am. J. Kidney Dis. 47(2), 233-240 (2006).
14. Senthil Nayagam L, Ganguli A, Rathi M et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: A pilot study. Nephrol. Dial. Transplant. 23(6), 1926-1930 (2008).
15. Chan TM, Lin AW, Tang SC et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology 12(6), 576-581 (2007).
16. KDIGO. Clinical practice guidelines for glomerulonephritis. Kidney Int. Suppl. 2, 186-197 (2012).
17. Ruggenenti P, Cravedi P, Chianca A et al. Rituximab in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23, 1416-1425 (2012).
18. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 360(9337), 923-924 (2002).
19. Fervenza FC, Abraham RS, Erickson SB et al.; Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin. J. Am. Soc. Nephrol. 5(12), 2188-2198 (2010).
20. Ruggenenti P, Cravedi P, Sghirlanzoni MC et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin. J. Am. Soc. Nephrol. 3(6), 1652-1659 (2008).
21. Ponticelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 9(3), 444-450 (1998).
22. Mathieu S, Pereira B, Dubost JJ, Lusson JR, Soubrier M. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology 51(6), 1107-1111 (2012).